1. Home
  2. AGEN

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Founded: 1994 Country:
United States
United States
Employees: N/A City: LEXINGTON
Market Cap: 96.2M IPO Year: 2000
Target Price: $8.00 AVG Volume (30 days): 488.3K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -10.59 EPS Growth: N/A
52 Week Low/High: $1.55 - $19.69 Next Earning Date: 03-11-2025
Revenue: $103,463,000 Revenue Growth: -33.81%
Revenue Growth (this year): 32.21% Revenue Growth (next year): -13.21%

AGEN Daily Stock ML Predictions

Share on Social Networks: